MétaCan
Menu
Back to cohort
Record W4392818820 · doi:10.2967/jnumed.123.265997

Efficacy of [<sup>67</sup>Cu]Cu-EB-TATE Theranostic Against Somatostatin Receptor Subtype-2–Positive Neuroendocrine Tumors

2024· article· en· W4392818820 on OpenAlexaff
Fabrice Ngoh Njotu, Jessica Pougoue Ketchemen, Anjong Florence Tikum, Hanan Babeker, Brian D. Gray, Koon Y. Pak, Maruti Uppalapati, Humphrey Fonge

Bibliographic record

VenueJournal of Nuclear Medicine · 2024
Typearticle
Languageen
FieldMedicine
TopicNeuroendocrine Tumor Research Advances
Canadian institutionsRoyal University HospitalUniversity of Saskatchewan
Fundersnot available
KeywordsSomatostatin receptorNeuroendocrine tumorsSomatostatinCancer researchInternal medicineSomatostatin AnalogueSomatostatin receptor 2MedicineOncologyChemistryOctreotide

Abstract

fetched live from OpenAlex

β<sup>−</sup>-emitting <sup>177</sup>Lu-octreotate is an approved somatostatin receptor subtype 2 (SSTR2)–directed peptide receptor radionuclide therapy for the treatment of gastroenteropancreatic neuroendocrine tumors (NETs). However,<sup>177</sup>Lu-octreotate has fast pharmacokinetics, requiring up to 4 treatment doses. Moreover, <sup>177</sup>Lu is less than ideal for theranostics because of the low branching ratio of its γ-emissions, which limits its SPECT imaging capability. Compared with <sup>177</sup>Lu, <sup>67</sup>Cu has better decay properties for use as a theranostic. Here, we report the preclinical evaluation of a long-lived somatostatin analog, [<sup>67</sup>Cu]Cu-DOTA-Evans blue-TATE (EB-TATE), against SSTR2-positive NETs. <b>Methods:</b> The in&nbsp;vitro cytotoxicity of [<sup>67</sup>Cu]Cu-EB-TATE was investigated on 2-dimensional cells and 3-dimensional spheroids. In vivo pharmacokinetics and dosimetry were studied in healthy BALB/c mice, whereas ex vivo biodistribution, micro-SPECT/CT imaging, and therapy studies were done on athymic nude mice bearing QGP1.SSTR2 and BON1.SSTR2 xenografts. Therapeutic efficacy was compared with [<sup>177</sup>Lu]Lu-EB-TATE. <b>Results:</b> Projected human effective doses of [<sup>67</sup>Cu]Cu-EB-TATE for male (0.066 mSv/MBq) and female (0.085 mSv/MBq) patients are tolerable. In vivo micro-SPECT/CT imaging of SSTR2-positive xenografts with [<sup>67</sup>Cu]Cu-EB-TATE showed tumor-specific uptake and prolonged accumulation. Biodistribution showed tumor accumulation, with concurrent clearance from major organs over a period of 72 h. [<sup>67</sup>Cu]Cu-EB-TATE was more effective (60%) at eliminating tumors that were smaller than 50 mm<sup>3</sup> within the first 15 d of therapy than was [<sup>177</sup>Lu]Lu-EB-TATE (20%) after treatment with 2 doses of 15 MBq administered 10 d apart. Mean survival of [<sup>67</sup>Cu]Cu-EB-TATE–treated groups was 90 d and more than 90 d, whereas that of [<sup>177</sup>Lu]Lu-EB-TATE was more than 90 d and 89 d against vehicle control groups (26 d and 53 d), for QGP1.SSTR2 and BON1.SSTR2 xenografts, respectively. <b>Conclusion:</b> [<sup>67</sup>Cu]Cu-EB-TATE exhibited high SSTR2-positive NET uptake and retention, with favorable dosimetry and SPECT/CT imaging capabilities. The antitumor efficacy of [<sup>67</sup>Cu]Cu-EB-TATE is comparable to that of [<sup>177</sup>Lu]Lu-EB-TATE, with [<sup>67</sup>Cu]Cu-EB-TATE being slightly more effective than [<sup>177</sup>Lu]Lu-EB-TATE for complete remission of small tumors. [<sup>67</sup>Cu]Cu-EB-TATE therefore warrants clinical development.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.003
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.551
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.001
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.017
GPT teacher head0.311
Teacher spread0.294 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations10
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Nuclear MedicineSame topicNeuroendocrine Tumor Research AdvancesFrench-language works237,207